Published in Clin Exp Immunol on March 01, 1977
LM-Ag and LSP--two different target antigens involved in the immunopathogenesis of chronic active hepatitis? Clin Exp Immunol (1979) 1.59
Mallory bodies--immunohistochemical detection by antisera to unique non-prekeratin components. Gut (1980) 1.53
Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol (1979) 1.47
Antigens of the human liver. Clin Exp Immunol (1980) 1.25
Immunological reactions to liver-specific membrane lipoprotein (LSP) in experimental autoimmune liver disease in rabbits. Clin Exp Immunol (1982) 1.14
Detection and characterization of liver membrane autoantibodies in chronic active hepatitis by a solid-phase radioimmunoassay. Clin Exp Immunol (1980) 1.12
Mechanisms responsible for antibody-dependent, cell-mediated cytotoxicity to isolated hepatocytes in chronic active hepatitis. Gut (1979) 1.12
Histological and immunological investigation of liver-specific protein (LSP) immunized rabbits compared with patients with liver disease. Clin Exp Immunol (1981) 1.10
Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg positive chronic liver disease. Gut (1982) 1.07
Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol (1984) 1.04
Antibodies to a human liver membrane lipoprotein (LSP) in primary biliary cirrhosis. Gut (1980) 1.03
Autoantibody responses to liver-specific lipoprotein in mice. Immunology (1981) 0.98
Study of cellular immunity in experimental autoimmune hepatitis in mice. Clin Exp Immunol (1984) 0.97
Cell-mediated immunity to liver antigen in toxic liver injury. I. Occurrence and specificity. Clin Exp Immunol (1980) 0.95
Characterization and demonstration of human liver-specific protein (LSP) and apo-LSP. Clin Exp Immunol (1981) 0.95
Autoantibodies to liver-specific lipoprotein following hepatitis induced by mouse cytomegalovirus. Clin Exp Immunol (1983) 0.95
Lymphocyte transformation test with rabbit liver specific lipoprotein (RLSP) in chronic active hepatitis. Clin Exp Immunol (1979) 0.94
Liver cell surface expression of the antigen reacting with liver-kidney microsomal antibody (LKM). Clin Exp Immunol (1984) 0.91
Antibodies to liver membrane antigens in chronic active hepatitis (CAH). II. Specificity for autoimmune CAH. Clin Exp Immunol (1983) 0.91
Cell-mediated immunity to liver antigen in toxic liver injury. II. Role in pathogenesis of liver damage. Clin Exp Immunol (1980) 0.91
Hepatocyte damage induced by lymphocytes from patients with chronic liver diseases, as detected by LDH release. Clin Exp Immunol (1978) 0.90
Antibodies against human liver-specific protein (LSP) in acute and chronic viral hepatitis types A, B and non-A, non-B. Clin Exp Immunol (1981) 0.90
Immune responses to liver membrane antigens in patients with cystic fibrosis and liver disease. Arch Dis Child (1980) 0.90
Immune response to rabbit liver-specific lipoprotein in acute viral hepatitis. Clin Exp Immunol (1980) 0.89
Liver membrane antibodies in alcoholic liver disease: 1. prevalence and immunoglobulin class. Gut (1982) 0.86
Study of cellular immunity in experimental autoimmune hepatitis in mice: transfer of spleen cells sensitized with liver proteins. Clin Exp Immunol (1985) 0.86
Autoantibody to liver-specific lipoprotein in the mouse: regulation by naturally occurring autoantigen specific suppressor cells. Clin Exp Immunol (1984) 0.85
A species-non-specific liver plasma-membrane antigen and its involvement in chronic active hepatitis. Biochem J (1980) 0.85
Thymus-dependence of autoantibody responses to liver specific lipoprotein in the mouse. Clin Exp Immunol (1984) 0.85
Immunohistochemical localization of human liver specific protein using rabbit antisera and the avidin-biotin complex technique. Clin Exp Immunol (1985) 0.83
Inhibition of lymphocyte cytotoxicity in chronic active hepatitis. Clin Exp Immunol (1978) 0.81
Studies on experimental chronic active hepatitis in the rabbit. I. Induction of the disease by immunization with muscle as well as liver proteins. Br J Exp Pathol (1984) 0.80
Occurrence and significance of IgG liver membrane autoantibodies (LMA) in chronic liver diseases of different aetiology. Clin Exp Immunol (1983) 0.80
Hepatic membrane antibodies: studies of prevalence and specificity. Clin Exp Immunol (1985) 0.79
The relationship between liver-specific lipoprotein and the hepatocyte plasma membrane. Immunology (1987) 0.79
Effect of neonatal thymectomy on experimental autoimmune hepatitis in mice. Clin Exp Immunol (1987) 0.77
Inhibition of autoimmune hepatitis with hot labelled liver specific antigen. Clin Exp Immunol (1984) 0.77
The IgG antibody reactivity of sera from patients with active chronic hepatitis to a crude liver antigen and liver specific protein (LSP): analysis by ELISA and immunoblotting. Clin Exp Immunol (1988) 0.77
Liver membrane antibodies (LMA) recognize a 26-kD protein on the hepatocellular surface. Clin Exp Immunol (1990) 0.77
Lymphocyte cytotoxicity to autologous hepatocytes in alpha 1-antitrypsin deficiency. Gut (1984) 0.77
Sensitive avidin biotin based technique for identifying liver membrane antigens in tissue sections. J Clin Pathol (1988) 0.75
Analysis of the antigenic composition of liver specific lipoprotein using murine monoclonal antibodies. Gut (1985) 0.75
Leukaemic liver infiltration in AKR mice prematurely induced by immunization with human or allogeneic liver protein. Clin Exp Immunol (1981) 0.75
Studies on experimental chronic active hepatitis in the rabbit. II. Immunological findings. Br J Exp Pathol (1984) 0.75
Detection of antibodies to Chang liver cell in sera from patients with chronic liver diseases by 125I-labelled protein A binding assay and the effect of prednisolone and 6-mercaptopurine treatment on the level of the antibodies. Clin Exp Immunol (1984) 0.75
A monoclonal antibody to a rat hepato-renal membrane antigen. Clin Exp Immunol (1985) 0.75
Incidence of antibodies against rabbit liver specific lipoprotein (RLSP) in chronic active hepatitis. Clin Exp Immunol (1983) 0.75
Antibodies directed against human liver specific membrane lipoprotein (LSP) in marmosets experimentally infected with the hepatitis A virus. Clin Exp Immunol (1984) 0.75
Cross-reactions between serum proteins and water soluble liver tissue antigens of the nine-banded armadillo (Dasypus novemcinctus Linn.) and man. Clin Exp Immunol (1979) 0.75
Antibodies to liver cell membrane antigens in chronic active hepatitis (CAH). III. Partial characterization of the liver cell membrane antigens and comparison of reactivities in sera from patients with various liver diseases. Clin Exp Immunol (1984) 0.75
The nature of hepatic lymphocytic infiltrates in the tropical splenomegaly syndrome. Clin Exp Immunol (1982) 0.75
Immunological aspects of liver disease. Gut (1991) 0.75
Chronic active hepatitis. Gut (1991) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem (1969) 142.11
Phosphorus assay in column chromatography. J Biol Chem (1959) 60.56
Starch gel electrophoresis in a discontinous system of buffers. Nature (1957) 19.23
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet (1976) 3.16
Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med (1976) 2.57
Liver-specific antigens of different species. II. Localization of a membrane antigen at cell surface of isolated hepatocytes. Clin Exp Immunol (1974) 2.36
Tissue-specific antigens. Adv Immunol (1966) 2.15
Experimental chronic active hepatitis in rabbits following immunization with human liver proteins. Clin Exp Immunol (1972) 1.84
The distribution of soluble antigens in cellular structures of rat liver. Exp Cell Res (1960) 1.42
Soluble antigens in microsomes and other cell-fractions of rat liver. Nature (1958) 1.41
Removal of lipids from human plasma low-density lipoprotein by detergents. Biochemistry (1971) 1.30
Induction by allogeneic extracts of liver-specific precipitating autoantibodies in the mouse. Nature (1968) 1.27
The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Pathol (1976) 1.14
Immunological factors in the evolution of active chronic hepatitis and other autoimmune liver diseases. Clin Gastroenterol (1975) 1.04
Studies on thermostable liver-specific antigens. Int Arch Allergy Appl Immunol (1972) 0.90
Chemical characteristics of microsomal liver specific antigens in the rat. Br J Cancer (1967) 0.88
Succinylation of gamma globulin. Nature (1966) 0.86
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Meeting report: International Autoimmune Hepatitis Group. Hepatology (1993) 3.27
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet (1976) 3.16
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Liver transplantation. Curr Probl Surg (1979) 2.57
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol (1992) 2.31
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet (1982) 2.30
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet (1970) 2.25
Cytomegalovirus hepatitis in the adult. Lancet (1967) 2.20
Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ (1990) 2.18
Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain. Lancet (1973) 2.17
Assessment of non-mydriatic fundus photography in detection of diabetic retinopathy. Br Med J (Clin Res Ed) (1986) 2.16
Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care (1999) 2.16
Portal hypertension in idiopathic tropical splenomegaly. Lancet (1966) 2.16
Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14
Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem (1989) 2.14
Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax (2002) 2.12
A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology (1995) 2.11
H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet (1977) 2.10
Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure. Br Med J (1973) 2.09
Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis (1970) 2.09
Detection, treatment, and follow up of women with Chlamydia trachomatis infection seeking abortion in inner city general practices. BMJ (1989) 2.08
Simple hypothermic preservation for transporting human livers long distances for transplantation. Report of 12 cases. Transplantation (1977) 2.08
Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet (1971) 2.08